Neuroscience Is Becoming AbbVie's Quiet Powerhouse -- and Management Now Sees $12.7 Billion in Sales This Year

For years, AbbVie was primarily recognized for its immunology focus, with blockbuster drugs Humira, Skyrizi, and Rinvoq. However, the company is now investing significantly in neuroscience, expecting its neuroscience portfolio to generate approximately $12.7 billion in revenue by 2026. This expectation marks a $100 million increase from the previous guidance after a strong first half of the year.

While neuroscience generated $10.8 billion in revenue last year, it is now growing at a double-digit pace. AbbVie's neuroscience business has become increasingly diversified, with revenue climbing 20.3% year over year to $3.23 billion in the second quarter. Key contributors include Vraylar for schizophrenia and bipolar disorder, Botox for therapeutic use, Ubrelvy and Qulipta for migraine treatment, and Vyalev for Parkinson's disease.

The fastest-growing segment may be migraine drugs, with sales rising 22.6% year over year. Botox remains a durable asset, with additional applications beyond cosmetics. This diversification reduces AbbVie's reliance on any single therapeutic area, helping absorb risks from patent expirations and competitive launches. The company has also made an early investment in psychedelic-based medicines by acquiring Gilgamesh Pharmaceuticals' lead drug candidate, bretisilocin, for $906 million.

Despite being a minor player compared to industry giants like Nvidia, AbbVie's neuroscience division is rapidly growing and could become a major growth platform in the future.